{"entity":{"id":"pim1","kind":"target","name":"PIM1","aka":["Pim-1 proto-oncogene, serine/threonine kinase","Serine/threonine-protein kinase pim-1"],"tldr":"PIM1 is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response.","summary":"Proto-oncogene with serine/threonine kinase activity involved in cell survival and cell proliferation and thus providing a selective advantage in tumorigenesis. Exerts its oncogenic activity through: the regulation of MYC transcriptional activity, the regulation of cell cycle progression and by phosphorylation and inhibition of proapoptotic proteins (BAD, MAP3K5, FOXO3). Phosphorylation of MYC leads to an increase of MYC protein stability and thereby an increase of transcriptional activity.\n\nCIViC holds 5 clinical evidence items and 0 assertions across 5 variants, naming Ibrutinib. Open Targets scores its association with cancer at 0.70 (direct and indirect evidence; datatypes literature 0.99, genetic association 0.48, somatic mutation 0.83, clinical 0.12). IntOGen calls it a driver in 6 cohorts (3 activating, 3 loss-of-function), covering Diffuse Large B-Cell Lymphoma, NOS, Non-Hodgkin Lymphoma, Plasma Cell Myeloma.","asOf":"2026-09-23","links":[{"label":"HGNC HGNC:8986","url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:8986"},{"label":"UniProt P11309","url":"https://www.uniprot.org/uniprotkb/P11309/entry"},{"label":"NCBI Gene 5292","url":"https://www.ncbi.nlm.nih.gov/gene/5292"},{"label":"Ensembl ENSG00000137193","url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000137193"}],"tags":["cancer-genes-wave"],"related":["civic","open-targets","intogen"],"cancers":["non-hodgkin-lymphoma","multiple-myeloma","dlbcl","nsclc"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: Open Targets known-drug datatype score 0.12; IntOGen calls it an activating (Act) driver in 3 cohorts; IntOGen calls it a loss-of-function (LoF) driver in 3 cohorts; CIViC holds 5 clinical evidence items on its variants. Evidence tier \"clinical-evidence\" is the strongest of those signals.","Prevalence not recorded: none of the sources gives a positivity rate.","Diseases the sources name that have no OnCo cancer page yet, so they are not linked: Diffuse Large B-cell Lymphoma Activated B-cell Type."],"provenance":{"editedBy":"scripts/fetch-cancer-genes.ts (CIViC, Open Targets, IntOGen, HGNC, UniProt)","editedOn":"2026-09-23"},"symbol":"PIM1","role":["drug-target","oncogene-driver","tumour-suppressor","biomarker"],"evidenceTier":"clinical-evidence","sources":[{"label":"HGNC HGNC:8986","url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:8986","note":"approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)"},{"label":"UniProt P11309","url":"https://www.uniprot.org/uniprotkb/P11309/entry","note":"protein name, function text, keywords and locations (REST API)"},{"label":"CIViC gene PIM1","url":"https://civicdb.org/features/4286","note":"5 evidence items, 0 assertions, 5 variants; diseases: Diffuse Large B-cell Lymphoma Activated B-cell Type, Lung Non-small Cell Carcinoma, Diffuse Large B-cell Lymphoma (GraphQL API, CC0)"},{"label":"Open Targets ENSG00000137193","url":"https://platform.opentargets.org/target/ENSG00000137193/associations","note":"association with cancer (MONDO_0004992) 0.70; per-cancer scores at or above 0.5: diffuse large B-cell lymphoma 0.65, non-Hodgkin lymphoma 0.67 (GraphQL API, CC0)"},{"label":"IntOGen PIM1","url":"https://www.intogen.org/search?gene=PIM1","note":"driver in 6 cohorts (Act 3, LoF 3); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0"}],"specificity":"tumour-specific","distribution":"few-types","specificityNote":"Tumour-specific alteration: the catalogues call it an oncogene driver (IntOGen cohort analysis finds it activated more often than chance) and a tumour suppressor (IntOGen finds it knocked out more often than chance), so the direction differs between cohorts but the alteration is somatic either way; what a medicine would aim at or exploit is the altered form or its loss, absent from normal cells; no corpus medicine is aimed at it yet. HPA PIM1: RNA tissue enhanced (bone marrow 207 nTPM); blood lineage lineage enriched (granulocytes 323 nTPM); no normal tissue stained high. Distribution: 3 cancer families in the corpus carry a prevalence row, label threshold or catalogue link for it (Lymphoma, Multiple myeloma, Lung cancer (all types)); Open Targets associates it with 1 specific cancer type at or above 0.5 (diffuse large B-cell lymphoma). (Rule 6 of scripts/fetch-target-specificity.ts.)","specificitySources":[{"label":"UniProt P11309","url":"https://www.uniprot.org/uniprotkb/P11309/entry","note":"protein name, function text, keywords and locations (REST API)"},{"label":"CIViC gene PIM1","url":"https://civicdb.org/features/4286","note":"5 evidence items, 0 assertions, 5 variants; diseases: Diffuse Large B-cell Lymphoma Activated B-cell Type, Lung Non-small Cell Carcinoma, Diffuse Large B-cell Lymphoma (GraphQL API, CC0)"},{"label":"IntOGen PIM1","url":"https://www.intogen.org/search?gene=PIM1","note":"driver in 6 cohorts (Act 3, LoF 3); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0"},{"label":"Human Protein Atlas PIM1 tissue","url":"https://www.proteinatlas.org/ENSG00000137193-PIM1/tissue","note":"RNA tissue and blood lineage specificity, normal tissue antibody staining (version 25.1, CC BY-SA 3.0)"},{"label":"Open Targets ENSG00000137193 associations","url":"https://platform.opentargets.org/target/ENSG00000137193/associations","note":"cancer associations at or above 0.5 (CC0)"}],"hgnc":"HGNC:8986","ensembl":"ENSG00000137193","uniprot":"P11309","entrez":"5292","firstDescribed":1987,"firstDescribedBasis":"sequence","firstDescribedNote":"Earliest sequence paper UniProt cites for the protein: Zakut-Houri et al, Gene, 1987, \"The cDNA sequence and gene analysis of the human pim oncogene\".","firstDescribedSource":"https://pubmed.ncbi.nlm.nih.gov/3475233/","biology":"Proto-oncogene with serine/threonine kinase activity involved in cell survival and cell proliferation and thus providing a selective advantage in tumorigenesis. Exerts its oncogenic activity through: the regulation of MYC transcriptional activity, the regulation of cell cycle progression and by phosphorylation and inhibition of proapoptotic proteins (BAD, MAP3K5, FOXO3). Phosphorylation of MYC leads to an increase of MYC protein stability and thereby an increase of transcriptional activity. The stabilisation of MYC exerted by PIM1 might explain partly the strong synergism between these two oncogenes in tumorigenesis. Mediates survival signalling through phosphorylation of BAD, which induces release of the anti-apoptotic protein Bcl-X(L)/BCL2L1. Phosphorylation of MAP3K5, another proapoptotic protein, by PIM1, significantly decreases MAP3K5 kinase activity and inhibits MAP3K5-mediated phosphorylation of JNK and JNK/p38MAPK subsequently reducing caspase-3 activation and cell apoptosis. Location: Cytoplasm; Nucleus; Cell membrane (UniProt). Locus 6p21.2 (HGNC).","whereFound":["Non-Hodgkin lymphoma: Open Targets association 0.67 with non-Hodgkin lymphoma (MONDO_0018908); IntOGen driver in 1 cohort (NHL)","Multiple myeloma: IntOGen driver in 1 cohort (PCM)","Diffuse large B-cell lymphoma: Open Targets association 0.65 with diffuse large B-cell lymphoma (MONDO_0018905); CIViC evidence names this disease","Non-small-cell lung cancer: CIViC evidence names this disease"],"targetClass":"kinase","prevalence":[]},"route":"/targets/pim1/","neighbours":{"collection":[{"id":"civic","kind":"collection","name":"CIViC","route":"/collections/civic/"},{"id":"intogen","kind":"collection","name":"IntOGen","route":"/collections/intogen/"},{"id":"open-targets","kind":"collection","name":"Open Targets Platform","route":"/collections/open-targets/"}],"cancer":[{"id":"dlbcl","kind":"cancer","name":"Diffuse large B-cell lymphoma","route":"/cancers/dlbcl/"},{"id":"multiple-myeloma","kind":"cancer","name":"Multiple myeloma","route":"/cancers/multiple-myeloma/"},{"id":"non-hodgkin-lymphoma","kind":"cancer","name":"Non-Hodgkin lymphoma (all types)","route":"/cancers/non-hodgkin-lymphoma/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}]}}